Altimmune Inc (ALT)

$3.53 -0.09 (-2.49%)
Market Cap 455.25M
Revenue (ttm) 40,000.00
Net Income (ttm) -88.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -220,225.00%
Debt to Equity Ratio 0.15
Volume 2,529,000
Avg Vol 4,693,808
Day's Range N/A - N/A
Shares Out 130.07M
Stochastic %K 22%
Beta 0.13
Analysts Strong Sell
Price Target $17.22

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
2MargaritaLunch
2MargaritaLunch Mar. 18 at 12:19 AM
$ALT one bone please
0 · Reply
Turribull
Turribull Mar. 17 at 11:39 PM
$ALT Someone slip this under Durso’s bathroom door. Thanks!
1 · Reply
Amnesiac
Amnesiac Mar. 17 at 11:35 PM
$ALT Can someone ask Jefferies about Altimmune meeting and if Luis Sanay will attend or if it is a mistake. Thank you! @Diapers_Tequila can you ask Lee about that too?
0 · Reply
Diapers_Tequila
Diapers_Tequila Mar. 17 at 11:06 PM
$ALT I miss old school Altimmune, those boys just turned off the phone at the annual meeting instead of taking questions….these new gangstas are adding 200 million shares, changing by-laws, making you get a doctorate degree in order to ask a question at the annual meeting. This gravy train is elite.
3 · Reply
2MargaritaLunch
2MargaritaLunch Mar. 17 at 10:23 PM
$ALT still waiting on conference blitz pr….
0 · Reply
Ultrasound
Ultrasound Mar. 17 at 10:13 PM
$ALT The audacity of Durso. He’s been on the job for 10 whole weeks and hasn't even sold the company yet? Outrageous. Meanwhile, he has the gall to let SP skyrocket 85% in his first 21 days. Honestly, where does he get off providing that kind of shareholder value so quickly? Truly a monster. And having the temerity to buy shares in Dec & March shows he's truly savage for believing in Pemvi!
3 · Reply
CrappieDude
CrappieDude Mar. 17 at 9:23 PM
$ALT damn this board has changed. Used to be an Adocia nugget would draw some level of excitement? WTH they doing over there hiring 9 new lab positions?
3 · Reply
StockDark
StockDark Mar. 17 at 9:18 PM
$ALT jus received voting email.
1 · Reply
TTC1
TTC1 Mar. 17 at 9:17 PM
$ALT no single catalyst can make it alive so far. Sad
0 · Reply
Thepatientone
Thepatientone Mar. 17 at 9:14 PM
$ALT BIC - Scenario A — Conservative ($20 stock) Assumptions: MASH success probability: 40% Obesity = secondary / not dominant Peak sales: MASH: $2–3B Valuation multiple: ~3x sales Enterprise Value ≈ $6–8B Per share: $6.5B ÷ 160M ≈ $40/share theoretical Apply risk discount (~50%): $20/share Scenario B — Base Case ($50 stock) Assumptions: MASH success: 60% Obesity adds meaningful value Peak sales: MASH: $4–5B Obesity: optional upside EV ≈ $10–12B Per share: $11B ÷ 160M ≈ $68/share Apply execution + dilution discount: ~$50/share Scenario C — Bull Case ($100+ stock) Assumptions: MASH success: high (70–80%) Obesity differentiation proven (muscle preservation) Dual indication pricing power Peak sales: MASH: $6–8B Obesity: $5–10B (partial penetration) EV: $20–30B Per share: $25B ÷ 160M ≈ $156/share Apply discount: $80–120/share
2 · Reply
Latest News on ALT
Altimmune: The High Cost Of Going Solo (Rating Downgrade)

Mar 12, 2026, 2:47 PM EDT - 5 days ago

Altimmune: The High Cost Of Going Solo (Rating Downgrade)

Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 12, 2026, 1:02 PM EDT - 5 days ago

Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript

Mar 5, 2026, 2:15 PM EST - 12 days ago

Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Mar 5, 2026, 7:00 AM EST - 12 days ago

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Altimmune to Participate in Upcoming Investor Conferences

Mar 2, 2026, 7:30 AM EST - 15 days ago

Altimmune to Participate in Upcoming Investor Conferences

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Feb 26, 2026, 7:30 AM EST - 19 days ago

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 6 weeks ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

AMGN GPCR LLY NVO PFE VKTX

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

Jan 29, 2026, 5:54 PM EST - 6 weeks ago

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

Altimmune (ALT) Shares Slide On $75 Million Stock Offering

Jan 28, 2026, 4:13 PM EST - 6 weeks ago

Altimmune (ALT) Shares Slide On $75 Million Stock Offering

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Jan 27, 2026, 9:25 PM EST - 6 weeks ago

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Jan 5, 2026, 7:30 AM EST - 2 months ago

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Dec 23, 2025, 7:42 PM EST - 2 months ago

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Dec 19, 2025, 12:57 PM EST - 3 months ago

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript

Dec 19, 2025, 11:37 AM EST - 3 months ago

Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Dec 19, 2025, 6:42 AM EST - 3 months ago

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Dec 19, 2025, 6:30 AM EST - 3 months ago

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Altimmune Announces CEO Transition and Succession Plan

Dec 1, 2025, 7:30 AM EST - 3 months ago

Altimmune Announces CEO Transition and Succession Plan

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:30 AM EST - 3 months ago

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 20, 2025, 3:03 PM EST - 4 months ago

Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Altimmune: Probing Pemvi's MASH Data

Nov 14, 2025, 3:23 AM EST - 4 months ago

Altimmune: Probing Pemvi's MASH Data

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Nov 11, 2025, 8:51 AM EST - 4 months ago

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Nov 7, 2025, 8:05 AM EST - 4 months ago

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 2:26 PM EST - 4 months ago

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 7:00 AM EST - 4 months ago

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Altimmune to Participate in Two Upcoming Investor Conferences

Nov 5, 2025, 7:30 AM EST - 4 months ago

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Nov 3, 2025, 7:30 AM EST - 4 months ago

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Oct 30, 2025, 7:30 AM EDT - 4 months ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Oct 20, 2025, 7:30 AM EDT - 5 months ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

Oct 6, 2025, 10:09 AM EDT - 5 months ago

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 5, 2025, 11:40 PM EDT - 5 months ago

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 3, 2025, 9:50 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 30, 2025, 10:20 AM EDT - 6 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Sep 29, 2025, 7:30 AM EDT - 6 months ago

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 21, 2025, 8:39 AM EDT - 6 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

Sep 19, 2025, 10:27 AM EDT - 6 months ago

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

SLQT

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Sep 18, 2025, 8:45 AM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Sep 15, 2025, 7:30 AM EDT - 6 months ago

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 11:20 AM EDT - 6 months ago

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Aug 27, 2025, 5:17 PM EDT - 7 months ago

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

2MargaritaLunch
2MargaritaLunch Mar. 18 at 12:19 AM
$ALT one bone please
0 · Reply
Turribull
Turribull Mar. 17 at 11:39 PM
$ALT Someone slip this under Durso’s bathroom door. Thanks!
1 · Reply
Amnesiac
Amnesiac Mar. 17 at 11:35 PM
$ALT Can someone ask Jefferies about Altimmune meeting and if Luis Sanay will attend or if it is a mistake. Thank you! @Diapers_Tequila can you ask Lee about that too?
0 · Reply
Diapers_Tequila
Diapers_Tequila Mar. 17 at 11:06 PM
$ALT I miss old school Altimmune, those boys just turned off the phone at the annual meeting instead of taking questions….these new gangstas are adding 200 million shares, changing by-laws, making you get a doctorate degree in order to ask a question at the annual meeting. This gravy train is elite.
3 · Reply
2MargaritaLunch
2MargaritaLunch Mar. 17 at 10:23 PM
$ALT still waiting on conference blitz pr….
0 · Reply
Ultrasound
Ultrasound Mar. 17 at 10:13 PM
$ALT The audacity of Durso. He’s been on the job for 10 whole weeks and hasn't even sold the company yet? Outrageous. Meanwhile, he has the gall to let SP skyrocket 85% in his first 21 days. Honestly, where does he get off providing that kind of shareholder value so quickly? Truly a monster. And having the temerity to buy shares in Dec & March shows he's truly savage for believing in Pemvi!
3 · Reply
CrappieDude
CrappieDude Mar. 17 at 9:23 PM
$ALT damn this board has changed. Used to be an Adocia nugget would draw some level of excitement? WTH they doing over there hiring 9 new lab positions?
3 · Reply
StockDark
StockDark Mar. 17 at 9:18 PM
$ALT jus received voting email.
1 · Reply
TTC1
TTC1 Mar. 17 at 9:17 PM
$ALT no single catalyst can make it alive so far. Sad
0 · Reply
Thepatientone
Thepatientone Mar. 17 at 9:14 PM
$ALT BIC - Scenario A — Conservative ($20 stock) Assumptions: MASH success probability: 40% Obesity = secondary / not dominant Peak sales: MASH: $2–3B Valuation multiple: ~3x sales Enterprise Value ≈ $6–8B Per share: $6.5B ÷ 160M ≈ $40/share theoretical Apply risk discount (~50%): $20/share Scenario B — Base Case ($50 stock) Assumptions: MASH success: 60% Obesity adds meaningful value Peak sales: MASH: $4–5B Obesity: optional upside EV ≈ $10–12B Per share: $11B ÷ 160M ≈ $68/share Apply execution + dilution discount: ~$50/share Scenario C — Bull Case ($100+ stock) Assumptions: MASH success: high (70–80%) Obesity differentiation proven (muscle preservation) Dual indication pricing power Peak sales: MASH: $6–8B Obesity: $5–10B (partial penetration) EV: $20–30B Per share: $25B ÷ 160M ≈ $156/share Apply discount: $80–120/share
2 · Reply
ApesOnParade
ApesOnParade Mar. 17 at 9:12 PM
$ALT ill tell you this much. No matter how you feel about the SP right now never sell in a downturn. At least wait for that weird little pump when the market has to correct momentarily and sale into the small blimp.
0 · Reply
Thepatientone
Thepatientone Mar. 17 at 9:12 PM
$ALT BIC - Relative Positioning of ALT ALT sits in a unique position: ALT Dual indication (MASH + obesity) Needs capital MDGL Approved Single indication VKTX Strong obesity No MASH AKRO / 89bio Strong MASH No obesity
1 · Reply
StockDark
StockDark Mar. 17 at 8:57 PM
$ALT no transparency.
1 · Reply
JuggernautRaider
JuggernautRaider Mar. 17 at 8:54 PM
$DERM appreciate the heads up @hofno2003 . I need to do a deep dive on Emrosi. This may join my Top Ten Biotech list along with $ALT $IMRX and of course $TNXP
0 · Reply
Amnesiac
Amnesiac Mar. 17 at 8:43 PM
$ALT a few things helping me to keep little faith… - AGM moved to April - Global ph3 trial - EMA alignment, oral partnership, ph3 protocol confirmations should come soon… But man am I depressed and I feel stupid to hope so much…
2 · Reply
Cryptobearcat
Cryptobearcat Mar. 17 at 8:43 PM
$ALT My not so conspiracy theory. Tern dropped its obesity program by end of Oct 2025, its short interest magically dropped by 34% and its share price has soared. Mazdutide the only other glucagon GLP1 drug that is ahead of Pemvi, and is approved in China. LLY owns its rights yet has done nothing with it outside of China. Almost as if LLY bought its rights to bury it. So are these 2 things related? I think so. The rumor is Goldman sachs turned bearish on Alt March 2024 when Garg turned down an offer. Alt share price was at high of 12 on closing, 14 intra day march 1st. At around the same time NASH early results were coming back. I believe may be LLY or some other BP offered similar # to carmot but Garg saw early NASH results and wanted the value added. This is unfortunately the curse of Pemvi being able to do everything. Then during talks for NASH, AUD / ALD now come into the picture. Which again interfered with potential deal. continued...
4 · Reply
THE_ORJINAL
THE_ORJINAL Mar. 17 at 8:42 PM
$ALT Their ERs and fireside chats should reflect this better.
2 · Reply
VINCE_CARTER
VINCE_CARTER Mar. 17 at 8:35 PM
$ALT 👇 I'm shorting oil as of today via $SCO Either supply normalizes and prices drift down Or Prices stay high and economy collapses and prices collapse Timeframe/horizon important Lots of ways to play an oil short
0 · Reply
BuddyBoy6975
BuddyBoy6975 Mar. 17 at 8:35 PM
$ALT Thought I’d share this b/c this form is new to me. Can be a routine shareholder meeting filing OR Could imply something bigger. Time will tell
0 · Reply
OutlawBikerRR
OutlawBikerRR Mar. 17 at 8:32 PM
$ALT 3.17.2026 waiting the announcement… 🤣🤣🤣☠️☠️☠️
0 · Reply
Skilpad
Skilpad Mar. 17 at 8:21 PM
$ALT been invested here for more than 2 years, but reality is dawning on me. This new management team are going to dilute us into oblivion. Why have 4 meetings in a row with bankers if you have a partner lined-up? You are basically having a roadshow to sell more shares....really hope to be terribly wrong here as I have invested a very big chunk of my personal wealth in this company. Great potential but poor execution.
1 · Reply
August49
August49 Mar. 17 at 8:19 PM
$ALT I know that if we vote they out/ is going to be considered a vote of no confidence. I think Nasdaq will a point an interim mgm?
1 · Reply